Yan, C., Luo, W., Yang, J., Yang, J., Chen, S., Bergdorf, K., Hu, Q., Weiss, V. L., Johnson, D. B., Liu, Q., Richmond, A. (2026). RAS/MEK/PI3K pathway inhibition augments response to CD40 agonism by targeting CD11b+ Bregs thereby overcoming melanoma PD1-resistance. Nature Communications. https://doi.org/10.1038/s41467-025-67315-1